Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) Starts Presentation at 29th Annual Roth Conference
Juniper Pharmaceuticals (NASDAQ: JNP) is focused on developing therapeutics that address unmet medical needs in women's health. The company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the Crinone® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. For more information, visit the company’s website at www.juniperpharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and…
